Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated ...

A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will ...

What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger study with different cohorts. The randomized cohort of the study is cohort ...

Recent years have brought more targeted agents to the frontline treatment for patients with chronic lymphocytic leukemia. Strides have been made for the frontline treatment of patients with chronic ...

Deborah Stephens, DO, shares unmet needs in the current treatment landscape of CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tara Graff, ...

Ibrutinib, a BTK inhibitor, is effective in treating relapsed CLL, with combination therapies improving response rates. Combination therapy with ibrutinib and venetoclax, guided by MRD, enhances ...

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA®) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...

(RTTNews) - BeiGene, Ltd. (BGNE), a clinical-stage pharmaceutical company, Tuesday announced that its Bruton's tyrosine kinase or BTK inhibitor has been granted notice of compliance by Health Canada ...

For most of us, a cancer diagnosis would be the worst possible news. But a remarkable new documentary, Second Winds, captures ...

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer affecting white blood cells, predominantly diagnosed in adults over 60. The CLL market is expanding due to the aging population, ...